• In late April 2026, Cadence Design Systems reported first-quarter revenue of US$1,474.22 million and net income of US$335.66 million, and raised its full-year 2026 guidance for revenue to US$6.13–US$6.23 billion and GAAP diluted EPS to US$4.39–US$4.49 while continuing share repurchases under its long-running buyback program.
• A key underpinning of this improved outlook is strong demand for Cadence’s AI-driven design platforms, reinforced by an expanded alliance with TSMC that targets advanced process nodes such as N3, N2, A16 and A14 for next-generation AI and high-performance computing chips.
• With management lifting full-year guidance on the back of AI-led demand and a larger TSMC collaboration, we’ll assess how this reshapes Cadence’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Cadence Design Systems Investment Narrative Recap

To own Cadence, you need to believe its AI-first design platforms and deep foundry alliances will keep it central to next generation chip development. The near term catalyst is continued adoption of its AI and agentic tools, while a key risk is intensifying competition in EDA and IP that could pressure pricing. The latest Q1 beat and guidance raise signal that, for now, AI demand is supporting that thesis, but do not remove competitive or geopolitical risk.

The expanded alliance with TSMC around N3, N2, A16 and A14 feels most relevant here, because it ties Cadence’s AI-driven tools directly into the most advanced manufacturing nodes for AI and high performance computing. That strengthens one of its core catalysts: being embedded in customers’ most complex designs and 3D IC roadmaps. At the same time, it raises the stakes on partnership execution and on how exposed Cadence is if foundry technology or customer roadmaps shift.

Yet underneath the upgraded outlook, investors should still be aware of how rising open source and low cost EDA alternatives could start to erode Cadence’s pricing power and...

Cadence Design Systems' narrative projects $7.9 billion revenue and $2.1 billion earnings by 2029. This requires 14.2% yearly revenue growth and about a $1.0 billion earnings increase from $1.1 billion today.

Uncover how Cadence Design Systems' forecasts yield a $371.68 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$7.7 billion and earnings of roughly US$1.6 billion by 2029, and worrying more about open source competition and pricing pressure than the consensus. This new AI driven guidance and TSMC expansion could challenge that pessimism, or reinforce it if you think the bar has simply been raised, so it is worth weighing both stories before you decide how you see Cadence’s future.

Explore 8 other fair value estimates on Cadence Design Systems - why the stock might be worth 49% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cadence Design Systems research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Cadence Design Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cadence Design Systems' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.